Testing Rina-S for Advanced Gastrointestinal Cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called Rina-S in people with advanced gastrointestinal cancers (like stomach, colon, or pancreatic cancer) that have spread or cannot be surgically removed. The drug is designed to help slow or stop cancer growth in people whose cancer has gotten worse despite recent treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed by biopsy or cell sample and be metastatic (spread) or unable to be surgically removed with intent to cure
- You must have measurable tumors on imaging scans that show progression (growth) on or after your most recent cancer treatment
- You must be in good enough overall health to tolerate treatment (ECOG performance status 0–1, meaning you can do most daily activities)
- You must have a life expectancy of at least 3 months
- You must have adequate organ and bone marrow function based on blood and other lab tests
- You cannot have severe ongoing gastrointestinal problems, recent bleeding in your GI tract, current ulcers, or perforation in your GI system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Hear when a new Gastrointestinal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.